Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

COLY-MYCIN S-2

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 11 USDMF, 5 CEP/COS, 2 JDMF, 1 KDMF, 23 NDC API, 10 VMF, 14 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

186 FDF Dossiers, 116 FDA Orange Book, 28 Europe, 7 Canada, 4 South Africa, 31 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM, OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION/DROPS;OTIC - EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML, OINTMENT;OPHTHALMIC - 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 6 SPI Pharma, 7 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Pfanstiehl, 12 Kirsch Pharma, 1 ACG Worldwide, 19 Actylis, 1 Aeon Procare, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 32 BASF, 3 CD Formulation, 10 Corel Pharma Chem, 3 DFE Pharma, 2 Esteem Industries, 4 Finar, 10 Gangwal Chemicals, 3 Ideal Cures, 22 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 1 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 11 Roquette, 17 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 2 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 2 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

44 Solubilizers, 43 Coating Systems & Additives, 42 Topical, 39 Fillers, Diluents & Binders, 36 Parenteral, 31 Thickeners and Stabilizers, 25 Direct Compression, 21 Emulsifying Agents, 21 Granulation, 20 Film Formers & Plasticizers, 19 Controlled & Modified Release, 19 Lubricants & Glidants, 13 Surfactant & Foaming Agents, 10 Taste Masking, 8 Co-Processed Excipients, 6 Chewable & Orodispersible Aids, 6 API Stability Enhancers, 5 Empty Capsules, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Disintegrants & Superdisintegrants, 1 Soft Gelatin

DIGITAL CONTENT

6 News #PharmaBuzz

6 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 5 Regulatory FDF Prices

MARKET PLACE

68 APIs, 4 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Pfizer CentreOne	U.S.A	PHARMACIA & UPJOHN COMPANY LLC Kalamazoo US	R1-CEP 1999-184 - Rev 03	Neomycin sulfate, Micronised and non-micronised	2020-04-21	Valid	Chemical		197
29/11/2025	Shandong Qilu King-Phar Pharmaceutical Co., Ltd	China	Shandong Qilu King-Phar Pharmaceutical Co., Ltd Pingyin CN	R1-CEP 2017-006 - Rev 00	Neomycin sulfate	2023-04-13	Valid	Chemical and TSE		197

COLY-MYCIN S-2

COLY-MYCIN S-2

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

11 USDMF

5 CEP/COS

2 JDMF

1 KDMF

23 NDC API

10 VMF

14 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

186 FDF Dossiers

116 FDA Orange Book

28 Europe

7 Canada

4 South Africa

31 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION/DROPS;OTIC - EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML

OINTMENT;OPHTHALMIC - 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Rochem International Inc

6 SPI Pharma

7 DKSH

4 Boai NKY Pharmaceuticals Ltd

3 Gangwal Healthcare

12 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 Pfanstiehl

12 Kirsch Pharma

1 ACG Worldwide

19 Actylis

1 Aeon Procare

3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

32 BASF

3 CD Formulation

10 Corel Pharma Chem

3 DFE Pharma

2 Esteem Industries

4 Finar

10 Gangwal Chemicals

3 Ideal Cures

22 Kerry

3 Kima Chemical

6 Lonza Capsugel

15 Microlex e.U

2 Nanjing Bold Chemical

2 Nippon Fine Chemical

1 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

1 Pharmatrans-Sanaq

4 Pluviaendo

1 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

11 Roquette

17 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

2 Sigachi Industries

2 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

2 Vasa Pharmachem

OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons